Expression Of ERCC1, DPYD In Site-specific Stage ⅢColon Cancer And Prognostic Analysis

Objective:To explore the difference of response to Oxaliplatin/Fluorouracil adjuvant chemotherapy and survival between site-specific stage Ⅲ colon cancer.Methods:Immunohistochemistry (IHC) analysis of the expression of ERCC1and DPYD was performed on tumour tissue of170patients with stage Ⅲ colon cancer receiving oxaliplatin/Fluorouracil adjuvant chemotherapy,and five-year disease-free survival (DFS) andoverall survival (OS) was collected via telephone survey. The influence of ERCCI and DPYD on5-year DFS and OS was constructed by Kaplan-Meier analysis.The difference between site-specific stage Ⅲ colon cancer in expression of ERCC1、DPYD was constructed by Kruskal-Wallis Test.Different5-year DFS and OS of site-specific stage Ⅲ colon cancer was constructed using Kaplan-Meier analysis.Results:1. Patients with positive ERCC1tumours had lower5-year DFS and OS than those with negative ERCC1tumours (DFS39.7%vs53.1%, HR:1.852,95%CI:1.145-2.994, P=0.009; OS:40.0%vs62.5%, HR:2.160,95%CI:1.250-3.731, P=0.016); Whereas there was no significant difference of DFS and OS between patients with pos-itive DPYD tumours and negtive DPYD tumours (DFS:44.0%vs 51.2%,HR:1.115,95%CI;0.690-1.801, P=0.443; OS:48.8%vs57.0%, HR:1.212,95%CI:0.654-1.923, P=0.408)。2.ERCC1positive rate between site-specific stage III colon cancer were significant-ly different(75.0%,66.7%,62.5%,58.1%,35.7%,42.9%,20.6%, from Caecum to Sigmoid colon respectively, P=0.000)。3.Survival between site-specific stage Ⅲ colon cancer were significantly different(DFS16.7%,33.3%,31.3%,48.4%,42.9%,57.1%,61.9%,from Caecum to Sigmoid colon respectively,P=0.017; OS:19.0%,37.0%,37.5%,51.6%,57.1%,60.0%,71.4%,respectively, P=0.002.Conclusion:1. ERCC1may be a negatively predictive factor of survival for stage Ⅲ colon cancer receiving oxaliplatin/Fluorouracil adjuvant chemotherapy.DPYD had no predictive value in this setting.2.site-specific stage Ⅲ colon cancer might response differently to oxaliplatin, Caecum cancer the worst,and Sigmoid colon cancer the best.3. site-specific stage Ⅲ colon cancer might be a group of heterogeneous diseases,Caecum cancer survive worst,and Sigmoid colon cancer survive the best.